Clinical Trial Update: Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Clemastine Fumarate as a remyelinating treatment for multiple sclerosis and internuclear ophthalmoplegia, currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Internuclear Ophthalmoplegia
• Multiple Sclerosis

Drugs mentioned

• Clemastine Fumarate (clemastine fumarate)

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: Multiple Sclerosis, Internuclear Ophthalmoplegia | Phase 3 | Status: RECRUITING